Dynavax reported a strong first quarter in 2025, achieving its highest first quarter net product revenue for HEPLISAV-B to date, with total revenues increasing by 34% year-over-year. The company also made significant progress in its pipeline, with key clinical trial milestones for shingles and plague vaccine programs, and new programs in pandemic influenza and Lyme disease entering clinical development.
Record HEPLISAV-B net product revenue of $65.0 million, a 36% increase year-over-year.
Total revenues reached $68.2 million, up 34% from the first quarter of 2024.
HEPLISAV-B's estimated U.S. market share increased to approximately 43%.
New pandemic influenza adjuvant and Lyme disease vaccine programs are planned to enter clinical development in 2025 and 2027, respectively.
Dynavax reaffirmed its full year 2025 financial guidance, expecting HEPLISAV-B net product revenue between $305 million and $325 million, and Adjusted EBITDA of at least $75 million.
Analyze how earnings announcements historically affect stock price performance